BioSpace News Archive

At 2 pm CET the same day as the announcement of the report Orexo invites analysts, investors and media to attend a presentation where Nikolaj Sørensen, CEO and Fredrik Järrsten, CFO, will present the report and host a Q&A.

Orbsen Therapeutics Limited, a global leader in stromal cell immunotherapies, announces encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for Diabetic Kidney Disease.

Today Esaote, a leading Italian company in the biomedical sector – in ultrasound, dedicated MRI and medical IT– presents the world premiere of MyLab™X90, its new premium ultrasound system.

Pearl Health, a leading technology company focused on physician enablement and risk bearing in value-based care, today announced that it has raised $75 million in its oversubscribed Series B funding round, led by Andreessen Horowitz’s Growth Fund and Viking Global Investors, with participation by AlleyCorp, SV Angel’s Growth Fund, and other leading investors.

Kurin, Inc., the inventor and manufacturer of the Kurin ® blood culture collection sets announced record revenues for 2022.

Longevity Biomedical, Inc. and Denali Capital Acquisition Corp. today announced that they have entered into a definitive business combination agreement (the “BCA”).

Nogra Pharma today announces it has entered into an out-licensing agreement with Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551), to further develop and commercialise NAC-GED-0507 in Japan for the treatment of acne vulgaris.

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the first interim safety, tolerability and immunogenicity findings from the Phase 1b/2 ABATE trial of its anti-amyloid-beta (Abeta) vaccine ACI-24.060 in patients with prodromal Alzheimer’s disease (AD).

CytomX Therapeutics, Inc. today announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas.

ONL Therapeutics, Inc. today announced that the company will share new clinical data on ONL1204 Ophthalmic Solution in the treatment of patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) at the upcoming 46th Annual Macula Society Meeting and the XXVth Biennial Meeting.